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ABSTRACT
Metabolic syndrome and type 2 diabetes are associated with increased risk of 
breast cancer development and progression. Methylglyoxal (MG), a glycolysis by-
product, is generated through a non-enzymatic reaction from triose-phosphate 
intermediates. This dicarbonyl compound is highly reactive and contributes to 
the accumulation of advanced glycation end products. In this study, we analyzed 
the accumulation of Arg-pyrimidine, a MG-arginine adduct, in human breast 
adenocarcinoma and we observed a consistent increase of Arg-pyrimidine in cancer 
cells when compared with the non-tumoral counterpart. Further immunohistochemical 
comparative analysis of breast cancer subtypes revealed that triple negative lesions 
exhibited low accumulation of Arg-pyrimidine compared with other subtypes. 
Interestingly, the activity of glyoxalase 1 (Glo-1), an enzyme that detoxifies MG, was 
significantly higher in triple negative than in other subtype lesions, suggesting that 
these aggressive tumors are able to develop an efficient response against dicarbonyl 
stress. Using breast cancer cell lines, we substantiated these clinical observations 
by showing that, in contrast to triple positive, triple negative cells induced Glo-1 
expression and activity in response to MG treatment. This is the first report that Arg-
pyrimidine adduct accumulation is a consistent event in human breast cancer with 
a differential detection between triple negative and other breast cancer subtypes. 
INTRODUCTION
Breast cancer represents the highest incidence of 
cancers and the second most common cause of death in 
women. This malignancy is characterized by a highly 
heterogeneous group of lesions with molecular and 
biochemical signatures, disease course, prognosis and 
treatment response. The classification based on gene 
expression patterns is commonly used to assess prognosis 
and therapy regimen. Breast malignant tumors are 
categorized into 4 main subtypes: luminal A (or HER2 
negative tumors), luminal B (or triple positive tumors), 
HER2 positive, and basal-like (or triple negative tumors) 
[1-3]. This latter group represents around 15-20% of 
newly diagnosed breast cancers [4]. Typically, these 
lesions are characterized by high proliferation rate, high 
histologic grade, tumor necrosis and poor prognosis [5, 
6]. Currently no treatment except chemoterapy is available 
for these patients. 
Emerging evidence shows that cancer is a metabolic 
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disease and that altered cellular energy metabolism is a 
common feature of malignant tumors. In recent studies, 
a link between obesity, diabetes and breast cancer has 
been made through insulin/insulin-like growth factor and 
PI3K/Akt/mTOR signaling pathways and through obesity-
induced chronic inflammation caused by adipose tissue 
dysfunction [7-9]. 
In proliferating cells, glucose metabolism and 
growth control are strictly linked [10, 11]. The Warburg 
effect according to which cells can rely on glycolysis 
as a major source of energy rather than oxidative 
phosphorylation, even in normoxic conditions, has 
been well described in many tumors including breast, 
melanoma, lung and colorectal cancer [12, 13]. 
Methylglyoxal (MG) is a highly reactive dicarbonyl 
compound and a potent glycating agent, mainly generated 
as a by-product of glycolysis through a spontaneous 
degradation of triosephosphates [14]. Accumulation of 
glycated proteins has been observed in several human 
diseases including diabetes, inflammation, aging, 
neurodegenerative disorders and cancer [15-25]. 
MG reacts with arginine, lysine and cysteine 
residues, nucleic acids and lipids generating advanced 
glycation end products (AGEs). In mammalian cells, 
MG is detoxified by the glyoxalase system, an enzymatic 
pathway consisting of two enzymes called glyoxalase 1 
(Glo-1) and glyoxalase 2 (Glo-2). Glo-1 catalyzes the 
isomerisation of the hemithioacetal, formed spontaneously 
from MG and reduced glutathione (GSH) to S-D-
lactoylglutathione. The second enzyme, Glo-2, converts 
the S-D-lactoylglutathione to D-lactate and recycles 
reduced glutathione [26, 27]. It has been shown that Glo-1 
expression and activity is increased in many human cancer 
types such as colon [28], prostate [29, 30], melanoma [31], 
lung [32], and breast [33] and that Glo-1 overexpression 
is correlated with cancer progression and drug resistance 
[34, 35]. In a recent proteomic study, Glo-1 expression has 
been shown to be positively correlated with high tumor 
grade in breast cancer [36]. 
The reaction of MG with arginine residues generates 
stable MG-moieties called Arg-pyrimidine [37, 38]. So 
far only few studies analyzed the expression of Arg-
pyrimidine adducts in cancer. Van Heijst and collaborators 
performed an Arg-pyrimidine immunohistochemical 
evaluation in 4 different types of human cancers, including 
a limited number of breast cancer lesions (n=5). Their 
conclusion was that Arg-pyrimidine level differs greatly 
between different types of tumors. To date the best-
studied Arg-pyrimidine-modified protein identified in 
malignant tumors is the heat shock protein 27 (Hsp27). 
This chaperone protein facilitates the proper refolding of 
damaged proteins and plays a key role in cell resistance to 
stress. In cancer cells, MG post-translationally modified 
Hsp27 prevented apoptotic cell death notably through the 
inhibition of cytochrome C-mediated caspase activation 
[39-41].
In this study, we evaluated for the first time Arg-
pyrimidine adducts accumulation in a large collection of 
breast cancer lesions categorized into the 4 main molecular 
subtypes using an immunohistochemistry approach. We 
demonstrated that triple negative breast tumors accumulate 
least Arg-pyrimidine adducts because of an efficient Glo-
1-based detoxification system. These findings suggest that 
sensitizing triple negative tumors to carbonyl stress may 
represent a good strategy for aggressive cancer subtypes. 
RESULTS
Arg-pyrimidine adducts are accumulated in 
human breast cancer tissues 
We evaluated the presence of Arg-pyrimidine 
adducts in 7 breast cancer tissues and in their non-tumoral 
Figure 1: Increased Arg-pyrimidine residues in human breast cancer tissues compared with the non-tumoral 
counterparts. Arg-pyrimidine adducts were evaluated in 7 breast cancer tissues (T) and in their non-tumoral counterpart (N) using 
western blot analysis (20 µg of proteins were loaded). The Ponceau S-stained membrane is shown as an indicator of equal protein loading. 
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counterparts by Western blot analysis. The antibody was 
specifically directed against Arg-pyrimidine adducts. As 
shown in Figure 1, tumoral lesions accumulated more Arg-
pyrimidine moieties in comparison with the corresponding 
non-tumoral counterparts. Some MG-modified proteins 
appeared enriched and/or uniquely observed in cancer 
lesions.
Triple negative breast tumors accumulate less 
Arg-pyrimidine adducts compared with other 
breast cancer subtypes 
Using immunohistochemistry, we next examined 
Arg-pyrimidine accumulation in 2 normal human breast 
samples and in a collection of 93 breast tumors categorized 
in triple negative, triple positive, HER2 positive and HER2 
negative. Arg-pyrimidine staining was mainly localized 
to the cytoplasm of breast epithelial cells, however in 
some cells a nuclear staining was also detectable. In good 
accordance with the Western blot analysis conducted on 
adjacent non tumoral breast samples, a moderate Arg-
pyrimidine immunostaining was detected in normal breast 
tissue (Figure 2A-C). It is noteworthy that endothelial 
cells lining the visible blood vessels adjacent to normal 
mammary glands were positive (Figure 2A). Interestingly, 
when we evaluated Arg-pyrimidine accumulation in 
the different breast cancer subtypes we found that Arg-
pyrimidine staining was significantly associated (chi-
square test p<0.0001) with the cancer subtypes. Indeed, 
we observed that the majority of triple negative lesions 
(Figure 2D) exhibited low staining for MG-adducts in 
comparison with the other subtypes (Figure 2E-G). In fact, 
more than 70% of triple negative breast tumors exhibited 
a negative to weak staining for Arg-pyrimidine while the 
majority of the 3 other breast cancer subtypes evaluated 
showed a moderate to strong level of MG-adducts (Figure 
2H). No significant staining was observed in tumor stroma 
in all the sections analyzed.
Triple negative breast cancer cell lines globally 
showed less Arg-pyrimidine adducts than other 
tumor subtypes
 Next, we investigated Arg-pyrimidine accumulation 
in HER2 positive (SKBR3), estrogen/progesterone 
receptor-positive (MCF-7) and 4 triple negative (MDA-
MB-231, MDA-MB-468, BT549, Hs579T) human 
breast cancer cell lines using Western blot analysis. All 
triple negative cell lines showed less Arg-pyrimidine 
accumulation compared with non-triple negative cell 
lines (Figure 3). This result is consistent with our 
immunohistochemical observations indicating that 
different breast cancer subtypes show distinct glycated 
adducts accumulation. 
Figure 2: Triple negative breast tumors accumulated less Arg-pyrimidine adducts in comparison with triple positive, 
HER2- and HER2+ tumors. (A) Arg-pyrimidine adducts are detectable in breast tissue from reduction mammoplasty. The panels (B) 
and (C) show a higher magnification (400x) of the cellular regions boxed in panel A. Triple negative lesions (D) exhibited a significantly 
lower accumulation of Arg-pyrimidine residues compared to triple positive (E), HER2- (F) and HER2+ (G) subtypes, magnification 100x. 
Immunohistochemical quantification (H) was performed as described in Materials and Methods section.
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Increased glyoxalase 1 (Glo-1) activity in triple 
negative tissues 
To further explore the observed difference in 
accumulation of glycated adducts, serial sections were 
stained for both Arg-pyrimidine (Figure 4A, a and b) and 
the main MG-detoxifying enzyme, Glo-1 (Figure 4A, 
c and d). High Glo-1 staining was observable in both 
tumor subtypes regardless of the different levels of Arg-
pyrimidine and no significant association (Fisher’s exact 
test) was observed between the staining intensity and the 
different cancer subtypes evaluated. Indeed, most of triple 
negative (80%) and triple positive (90%) lesions expressed 
high levels of Glo-1 (Figure 4B). Therefore, we sought to 
examine the enzymatic activity of Glo-1 in these samples. 
The measurement performed on tissue extracts showed 
a significant increase in Glo-1 activity in triple negative 
tumors when compared with triple positive ones (Figure 
5). 
Only triple negative breast cancer cell lines 
respond to MG stimulation by increasing their 
Glo-1 expression and activity
To investigate whether triple negative breast cancer 
cells could respond to MG stimulation by increasing Glo-1 
expression and activity, we treated breast cancer cells with 
MG at 300, 500 or 1000 µM during 6 hours. MG treatment 
neither affected the level of expression (Figure 6A) nor the 
activity (Figure 6B) of Glo-1 in MCF-7 and SKBR3 breast 
cancer cells. However, MG significantly induced a dose-
dependent effect on both Glo-1 expression and activity 
Figure 3: Low basal Arg-pyrimidine adducts 
accumulation in triple negative breast cancer cell 
lines. Arg-pyrimidine levels were evaluated using Western blot 
analysis on 6 breast cancer cell lines including SKBR3, MCF-7 
and 4 triple negative cell lines. In comparison with MCF-7 and 
SKBR3, all triple negative cells expressed less Arg-pyrimidine 
accumulation. Beta-actin expression was used to normalize 
the amount of loaded proteins. Semi-quantitation of total Arg-
pyrimidine adducts was done using beta-actin as a loading 
control.
Figure 4: Representative immunohistochemical staining of Glo-1 expression in triple negative versus triple positive 
human breast tissues. Glo-1 expression was evaluated in triple negative (n= 21) and triple positive (n= 21) breast cancer patients and 
one representative case of each is shown in panel A (c, d). The staining of Glo-1 was compared with the immunostaining for Arg-pyrimidine 
accumulation in the same triple negative (a) and triple positive (b) human specimen. Glo-1 is highly expressed in both triple positive and triple 
negative tumors and there was no significant difference between the two breast cancer subtypes. Glo-1 immunohistochemical quantification 
is shown in panel (B). The evaluation of the staining was performed as described in Materials and Methods section. Magnification 100x.
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in MDA-MB-231 and MDA-MB-468 triple negative cell 
lines (Figure 6A and B). Moreover, the 2-way ANOVA 
analysis proved that the 4 cell lines evaluated responded 
differently to MG treatment. Indeed, the interaction 
between MG concentration and cell lines significantly 
accounted for 32.11% of the total variance (p<0.0001). In 
order to exclude the potential MG acute toxicity on cancer 
cells, we also measured Glo-1 activity in MDA-MB-231 
and MCF-7 cells after 3 weeks of chronic treatment at 
lower concentrations of MG (5-50 µM) (Figure 7). As 
observed under acute treatment, triple negative cells 
showed a dose dependent induction of Glo-1 activity 
while MCF-7 cells maintained their basal level of Glo-
1 activity in all conditions tested (Figure 7). Moreover, 
the 2-way ANOVA analysis indicated that the interaction 
between MG concentration and the 2 cell lines accounted 
for 20.33% of the total variance (p<0.0015).
DISCUSSION
While both cancer initiation and progression have 
been linked to oxidative stress [42] to date there is no 
clear evidence regarding the importance of the carbonyl 
stress in such processes. In cancer, reactive oxygen 
species (ROS) generate genomic damage and instability, 
activate mitogenic and survival mechanisms and favor 
cell invasion [43]. However, when the intracellular levels 
of oxidants reach a cytotoxic threshold, apoptotic and 
necrotic pathways are activated and cancer cells need to 
protect themselves from oxidative stress to survive [44]. 
Beside the well-established oxidative stress concept, 
endogenous dicarbonyl compounds such as MG also 
affect proteins, lipids and nucleic acids, leading to AGEs 
formation and carbonyl stress [45]. The carbonyl stress 
has been primarily described in diabetes where AGEs 
accumulation is a major event associated with diabetic 
complications [46]. High concentrations of MG and 
formation of AGEs have been reported in diabetic patients 
[47]. To date, known MG protein targets include albumin, 
hemoglobin, Sin3A, type IV collagen, alpha A-crystallin, 
protein p300 and 20S proteasome subunits, all associated 
with protein dysfunction [45]. 
Figure 7: Increased Glo-1 activity in triple negative 
cells exposed to chronic treatment with MG. Glo-1 
activity was measured in triple negative MDA-MB-231 and in 
ER/PR positive MCF-7 cells after three weeks treatment with 
low doses of MG. A significant increase of Glo-1 activity was 
observed only in triple negative cells. Results are the average of 
4 independent experiments.Data were statistically analyzed with 
two-way ANOVA followed by Bonferroni multiple comparisons 
(* p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 vs untreated cells).
Figure 6: Glo-1 expression and activity in human 
breast cancer cells upon MG stimulation. Breast cancer 
cells were treated with MG at 300, 500 or 1000 µM for 6 
hours. Only triple negative cancer cells are capable to respond 
to MG treatment by up-regulating both Glo-1 expression (A) 
and activity (B). No modulation of Glo-1 was observed in the 
other cell subtypes analyzed. Beta-actin expression was used 
to normalize the amount of loaded proteins. Semi-quantitation 
analysis was done using beta-actin as a loading control.Results 
are the average of independent experiments (n= 3). Data were 
statistically analyzed with two-way ANOVA followed by 
Bonferroni multiple comparisons (* p ≤ 0.05, **p ≤ 0.01 and 
***p ≤ 0.001 vs untreated cells).
Figure 5: Increased Glo-1 activity in triple negative 
breast cancer tumors in comparison with triple 
positive ones. Glo-1 activity was measured in breast cancer 
tumor samples comprising 4 triple positive and 5 triple negative 
lesions. Glo-1 enzymatic assay was performed on tissue total 
protein extracts as described in Material and Methods. Statistical 
comparison was performed by one-tailed Student’s t-test (*p ≤ 
0.05).
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Cancer cells predominantly produce energy by 
increasing their rate of glycolysis and as a consequence, 
triosephosphates-derived MG is increased in malignant 
tumor cells. MG is a potent cytotoxic compound and exerts 
an anti-tumor activity in vivo [48, 49] and was first viewed 
as a potential therapeutic agent in cancer [50]. However, 
the recent identification of MG-modified proteins in cancer 
cells brought the new possibility where MG may have pro-
tumorigenic effects. Indeed, MG induced the modification 
of Hsp-27 at arginine 188 (MG-Hsp27) in cancer cells and 
MG-Hsp27 facilitated cancer cell evasion from caspases-
dependent cell apoptosis [39-41]. 
Several types of protein modifications by MG 
have been reported [37, 51], among which those directed 
to the guanidino group of arginine residues are well 
represented. In this study, we detected Arg-pyrimidine 
adducts using immunohistochemistry in a large series of 
human breast cancer lesions. Non-tumoral breast tissue 
presented detectable Arg-pyrimidine basal accumulation 
which was consistently lower than the one observed in 
matched tumoral samples. We report for the first time 
the differential accumulation of Arg-pyrimidine moieties 
between the different breast cancer subtypes analyzed. 
We observed that triple negative breast cancer tumors 
had fewer detectable Arg-pyrimidine adducts than the 
ER/PR positive, HER2 negative and HER2 positive 
lesions. These original findings were further reinforced 
by our observation that Arg-pyrimidine adducts were 
significantly less detectable in triple negative breast 
cancer cell lines when compared to cell lines from 
other subtypes. Interestingly, while Arg-pyrimidine 
immunostaining was mainly cytoplasmic some nuclei 
presented a positive staining suggesting the presence of 
nuclear MG-modified proteins in cancer cells. Using the 
same antibody, Nakadate and collaborators have reported 
the accumulation of Arg-pyrimidines in the nucleus of 
neural cells [52]. Ongoing experiments in our laboratory 
aim to identify new potential nuclear targets of MG such 
as transcription factors and co-regulator proteins in breast 
cancer cells. 
Glo-1 is the main enzyme involved in the 
detoxification of MG. It has been reported that Glo-1 
expression and activity are increased in breast tumor cells, 
most likely to control the high MG level spontaneously 
produced due to high glycolytic activity [33]. Glo-1 
expression was significantly higher in Her-2 positive 
breast tumors when compared with Her-2 negative 
ones. Thus, Her-2 positive tumors associated with an 
aggressive phenotype and a poor prognosis overexpress 
Glo-1 [53]. However, Glo-1 enzymatic activity was 
not evaluated in these tumors. In this study, Glo-1 
immunostaining performed on human triple negative 
and triple positive breast cancer lesions did not show 
any significant difference. Conversely, the measurement 
of Glo-1 activity performed on fresh samples showed a 
significant increase in Glo-1 enzymatic activity in triple 
negative tumors. Accordingly, we found that MDA-
MB-231 and MDA-MB-468 triple negative breast cancer 
cells adapted their level of Glo-1 expression and activity 
when treated with exogenous increasing doses of MG. 
Considering that MCF-7 cells remained stable for Glo-1 
under the same conditions, it is tempting to speculate that 
triple negative breast cancer cells increased their Glo-1 
activity as a control defense mechanism to prevent MG 
accumulation. This hypothesis was further sustained by 
the increased dose-dependent Glo-1 activity observed in 
both MDA-MB-231 and MDA-MB-468 cells in response 
to a chronic sub-toxic MG treatment when compared to 
MCF-7 cells. Such adaptive response to MG has been 
previously reported in Carl-1 human melanoma cells 
and was described as a defense mechanism against MG 
toxicity [54]. 
Our study adds to the growing body of evidence 
suggesting a major role of non-enzymatic glycation in 
cancer. The increase of Glo-1 activity may represent a 
strategy adopted by aggressive cancer cells such as triple 
negative breast cancer cells as a defense mechanism 
against the glycation damage induced by high intracellular 
MG accumulation. Our data suggest that inhibition of 
Glo-1 activity in triple negative breast tumors could be 
a new potential therapeutic strategy. In support of this 
concept, previous studies reported that a specific Glo-
1 inhibitor, S-p-bromobenzyl-glutathione cyclopentyl 
diester (SpBrGSHCp2), demonstrates an anti-tumor effect 
against Glo-1-overexpressing tumors that are unresponsive 
to conventional therapies. This Glo-1 inhibitor has been 
shown to increase the sensitivity of human leukemia 
cells to anti-tumor agents [55]. In human lung cells with 
high expression and activity of Glo-1, the treatment with 
SpBrGSHCp2 activated apoptosis through the activation of 
the stress-activated protein kinases JNK1 and p38 MAPK 
which finally led to caspase activation [32]. In human 
prostate cancer cells, the treatment with SpBrGSHCp2 
significantly affected tumor growth [14].
Oxidative stress has several pro-tumorigenic effects 
but it also exerts an anti-tumorigenic action as it has been 
linked to senescence and apoptosis. As a major actor of the 
carbonyl stress, MG also plays a dual role as a cytotoxic 
compound and as a pro-tumorigenic factor depending on 
the global cellular context. Moreover, one must consider 
that oxidative and carbonyl stresses are tightly linked 
together and may work in tandem to influence tumor 
phenotype. Indeed, the formation of both ROS and AGEs 
by cancer cells generates a sequence of reactions mutually 
enhancing each other [56].
Our study opens a new alley of investigations toward 
individualized cancer therapy based on the determination 
of metabolomic changes in tumors that might enable the 




Patient tissue samples were obtained from the 
Pathology Department of the University Hospital of Liège 
in accordance with ethical guidelines of the University 
of Liège (Liège, Belgium). The immunohistochemical 
analysis was conducted on a collection of 93 breast 
cancer patients grouped into 4 biological subtypes (triple 
negative, triple positive, HER2- and HER2+) and 2 normal 
breast specimens obtained from reduction mammoplasties. 
ER, PR, and HER2 status was evaluated routinely by 
anatomo-pathological examination. In this series, HER2 
positive tumors were all negative for ER and PR receptors 
and all HER2 negative tumors were positive for both 
hormone receptors. Patients received standard guideline-
based according to standard guideline: hormonotherapy 
for all patients with ER-positive tumours, trastuzumab 
for those with HER2-positive tumours, anthracycline 
chemotherapy for high-risk lymph node-negative 
lesions, and anthracycline plus taxane chemotherapy for 
lymph node positive tumors. Western blot analysis was 
conducted on total protein extracts from 7 breast ductal 
adenocarcinoma (grade II and III) and their matched non-
tumoral counterpart.
Cell lines
Human breast cancer cell lines BT549, Hs578T, 
MCF-7, MDA-MB-231, SKBR3 were obtained from the 
American Type Culture Collection (ATCC) and MDA-
MB-468 cell line was a kind gift from Prof. Sebastiano 
Andò (Laboratory of General Pathology, University of 
Calabria, Italy). Breast cancer cell lines usually cultured 
in DMEM (standard glucose concentration of 4.5 g/L, 
Lonza) containing 10% fetal bovine serum, and 2 mM 
L-glutamine, were adapted to grow in DMEM medium 
with a glucose concentration of 1 g/L for several weeks. 
This glucose level is physiological and reflects the in vivo 
concentration in human serum. Conversely, the routine 
culture media concentration of 4.5 g/L corresponded to a 
diabetic condition.
Western blot analysis and antibodies
 Cell and tissue samples were extracted in RIPA 
buffer (150 mM NaCl, 0.5% Na-deoxycholate, 1% Triton 
X-100, 0.1%SDS, 50 mM Tris-HCl pH 7.5) containing 
protease and phosphatase inhibitors (Roche). After 
incubation under rotation at 4°C for 40 minutes, lysates 
were then centrifugated at 14,000 g for 15 minutes at 4°C 
to remove insoluble debris. Protein concentrations were 
determined using the BCA assay (Pierce). Protein extracts 
were then separated by SDS-PAGE and transferred to a 
PVDF membrane. Next, the membranes were blocked for 
1h in TBS-Tween containing 5% nonfat dried milk (Bio-
Rad) and incubated with the primary antibodies overnight 
at 4°C. The membranes were probed with anti-Arg-
pyrimidine (mAb6B) monoclonal antibody (1:10,000). 
The specificity of this antibody has been previously 
confirmed by competitive ELISA and it has been shown to 
not react with other MG-arginine adducts such as 5-hydro-
5-methylimidazolone and tetrahydropyrimidine [57]. 
Anti-Human Glyoxalase I monoclonal antibody (1:1,000 
dilution, cat#02-14, BioMac Leipzig) and anti-beta-
actin (1:5,000 dilution, cat# A5441, Sigma) were used. 
Horseradish peroxidase-conjugated secondary antibodies 
[anti-mouse, 1:6,000 dilution (Dako) or anti-rabbit 1:3,000 
(Invitrogen)] were used to visualize bound primary 
antibodies, with the ECL Western blotting substrate 
(Pierce). Where indicated, ImageJ software 1.46r (imagej.
nih.gov) was used for semi-quantitation using beta-actin 
as a loading control.
Immunohistochemistry on breast tissues
 Formalin-fixed paraffin-embedded sections 
were deparaffinized in xylene and rehydrated. To block 
endogenous peroxidase activity, the tissues were treated 
with 3% hydrogen peroxide in methanol for 30 minutes 
and washed in PBS for 20 minutes. Antigen retrieval 
was performed in 10 mM sodium citrate, pH 6.0 for 40 
minutes at 95°C. Sections were then incubated with 1.5% 
normal horse serum (cat#S-2000, Vector Laboratories) 
for 30 minutes to block the nonspecific serum-binding 
sites. Then, sections were incubated with anti-Arg-
pyrimidine (1:2,000 dilution) or anti-human Glyoxalase 
I (1:100 dilution) antibody overnight at 4°C. Antibody 
binding was detected using an anti-mouse biotinylated 
secondary (cat#BA-2000, Vector Laboratories) for 
30 minutes followed by incubation with the avidin-
biotin-peroxidase complex (Vectastain ABC Kit, Vector 
Laboratories). Immunoreactivity was revealed using 3,3′ 
diaminobenzidine tetrahydrochloride (DAB). The slides 
were counterstained with hematoxylin, dehydrated and 
mounted.
Evaluation of immunohistochemical staining
 The immunohistochemically stained sections 
were reviewed by two examiners including an 
anatomopathologist (E.B). Scoring of the staining was 
done according to the intensity of the staining (0, 1+, 2+, 
3+) and the percentage of positive cancer cells (0-25%, 
25-50%, 50-75%, 75-100%). The results obtained with 
the 2 scales were multiplied together as we previously 
described [58], yielding a single scale with steps of 0, 1+, 
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2+, 3+, 4+, 6+ and 9+ where 0, 1+ and 2+ were considered 
to be negative or weak staining and 3+, 4+, 6+ and 9+ 
were considered to be medium or strong staining.
Glyoxalase I assay
The activity of Glo-1 was measured in breast cancer 
cell lines and in human breast cancer tissues after protein 
extraction in RIPA buffer, by measuring the initial rate of 
S-D-lactoylglutathione formation from the hemimercaptal 
obtained by preincubation of an equimolar (1 mM) mixture 
of MG (cat#M0252, Sigma) and GSH (cat#G4251, Sigma) 
in 50 mM sodium phosphate buffer, pH 6.8, at 25°C for 15 
minutes. S-D-lactoylglutathione formation was followed 
spectrophotometrically by the increase in absorbance at 
240 nm at 25 °C. One enzyme unit was defined as the 
amount of enzyme that catalyzes the formation of 1 µmol 
of S-D-lactoylglutathione per minute at the saturating 
substrate concentration. 
Chronic treatment with MG. Breast cancer cells 
MDA-MB-231 and MCF-7 were treated with MG at 
different concentrations (5, 10, 20, 50 µM) for three 
weeks. The first week, a daily treatment was performed 
and for the remaining 2 weeks the treatment was repeated 
twice a week. Glo-1 activity was measured as described 
above on cell lysates after protein extraction in RIPA 
buffer.
Statistical analysis
 The data were statistically analyzed using either 
one-tailed Student t-test or with two-way ANOVA 
followed by Bonferroni multiple comparisons. One-
tailed t-test was selected because the H1 hypothesis 
was “triple negative Glo-1 activity is below or equal to 
triple positive”. Number of cases for Arg-pyrimidine or 
Glo-1 staining in each cancer subtypes was analyzed in a 
contingency table using chi-square test and Fisher’s exact 
test, respectively. P values less than 0.05 were considered 
statistically significant.
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